Avanos Medical, Inc. (NYSE:AVNS) Short Interest Down 13.3% in February

Avanos Medical, Inc. (NYSE:AVNS) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 2,954,825 shares, a decrease of 13.3% from the January 29th total of 3,409,612 shares. Approximately 6.5% of the shares of the stock are sold short. Based on an average daily volume of 586,195 shares, the short-interest ratio is presently 5.0 days. Based on an average daily volume of 586,195 shares, the short-interest ratio is presently 5.0 days. Approximately 6.5% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Finally, Wall Street Zen cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Avanos Medical currently has a consensus rating of “Reduce”.

Institutional Trading of Avanos Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in Avanos Medical by 1,596,514.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock valued at $167,287,000 after acquiring an additional 14,895,480 shares during the last quarter. Armistice Capital LLC increased its position in Avanos Medical by 28.0% during the 4th quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock worth $35,936,000 after purchasing an additional 700,000 shares in the last quarter. State Street Corp raised its holdings in Avanos Medical by 2.8% in the fourth quarter. State Street Corp now owns 1,954,785 shares of the company’s stock valued at $21,952,000 after buying an additional 53,523 shares during the period. Geode Capital Management LLC lifted its position in Avanos Medical by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock valued at $12,180,000 after buying an additional 16,980 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Avanos Medical by 20.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock worth $11,687,000 after buying an additional 176,716 shares during the period. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Trading Down 2.0%

Avanos Medical stock traded down $0.28 during trading on Thursday, hitting $13.60. The company’s stock had a trading volume of 141,878 shares, compared to its average volume of 598,778. The stock’s fifty day moving average is $13.20 and its 200 day moving average is $12.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $15.68. The stock has a market capitalization of $632.44 million, a price-to-earnings ratio of -8.61 and a beta of 1.07.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. During the same quarter in the prior year, the company posted $0.43 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, equities research analysts predict that Avanos Medical will post 1.32 EPS for the current year.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.